Washington Dc, DCNCT07091630Now EnrollingIRB Ready

Chronic Inflammatory Demyelinating Polyneuropathy Clinical Trial in Washington Dc, DC

Access cutting-edge chronic inflammatory demyelinating polyneuropathy treatment through this clinical trial at a research site in Washington Dc. Study-provided care at no cost to qualified participants.

Sponsored by argenx

Quick Self-Assessment

See if you qualify for this Washington Dc location

Preparing your pre-screening questions…

Expert Care in Washington Dc

Access chronic inflammatory demyelinating polyneuropathy specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related chronic inflammatory demyelinating polyneuropathy treatment provided free

Apply for This Washington Dc Location

Check if you qualify for this chronic inflammatory demyelinating polyneuropathy clinical trial in Washington Dc, DC

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Washington Dc

    Convenient for DC residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Washington Dc site if eligible
  4. 4Begin participation

About This Chronic Inflammatory Demyelinating Polyneuropathy Study in Washington Dc

The main purpose of this study is to demonstrate the efficacy and safety of empasiprubart in adults with CIDP. The study consists of a part A where participants will either receive empasiprubart or placebo for 24 weeks (6 months). Following part A, participants will enter part B in which all participants will receive empasiprubart for 96 weeks (24 months). More information can be found here: https://clinicaltrials.argenx.com/emnergize

Sponsor: argenx

Who Can Participate

Inclusion Criteria

Meets criteria for CIDP based on EAN/PNS Task Force CIDP guidelines, second revision (2021)
Has either typical CIDP or 1 of the following CIDP variants: motor CIDP (including motor-predominant CIDP), multifocal CIDP (also known as Lewis-Sumner syndrome), focal CIDP, or distal CIDP
Has residual disability and active disease
Has not received previous treatment for CIDP; or has stopped receiving CIDP treatment; or is receiving CIDP treatment (pulsed or oral corticosteroids, immunoglobulins, PLEX, or FcRn inhibitors)
Participants already receiving CIDP treatment will have to discontinue their CIDP treatment before first IMP administration and must be willing to switch to the study IMP

Exclusion Criteria

Meets the criteria for possible CIDP based on EAN/PNS Task Force CIDP guidelines, second revision (2021)
Sensory CIDP (including sensory-predominant CIDP)
Polyneuropathy of other causes
Clinical diagnosis of systemic lupus erythematosus (SLE)
Use of other long-acting immunomodulatory treatment or prior treatment (at any time) with total lymphoid irradiation or bone marrow transplantation

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Washington Dc?

Yes, this clinical trial (NCT07091630) has an active research site in Washington Dc, DC that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Chronic Inflammatory Demyelinating Polyneuropathy Treatment Options in Washington Dc, DC

If you're searching for chronic inflammatory demyelinating polyneuropathy treatment options in Washington Dc, DC, this clinical trial (NCT07091630) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Washington Dc research site is actively enrolling participants for this clinical trial. You'll receive care from experienced chronic inflammatory demyelinating polyneuropathy specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all chronic inflammatory demyelinating polyneuropathy clinical trials near you to find additional studies recruiting in your area.

More Multiple Myeloma Trials in Washington Dc, DC

See all multiple myeloma clinical trials recruiting in Washington Dc — not just this study.

Browse Multiple Myeloma Trials in Washington Dc

Ready to Join in Washington Dc?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Washington Dc, DC